Peptide LibraryKisspeptin-10 dosage in published studies and labels
These are the doses used for Kisspeptin-10 in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.
Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.
Last checked against primary sources:
Studied regimens and sources
Kisspeptin-10 itself has been given to humans only in short academic physiology studies, by intravenous bolus at doses on the order of 0.24 nmol/kg; a registered trial of its effect on insulin secretion has posted no results. Two further human studies often cited for it — an intranasal study at 12.8 nmol/kg and a bone-metabolism infusion — used kisspeptin-54, the 54-residue parent peptide, and are not evidence for the 10-residue fragment. No product is approved and no repeated-dosing regimen has been established.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 0.24 nmol/kg intravenous bolus (the only published kisspeptin-10 human dose) |
| Route | Intravenous |
| Frequency | Single bolus or short infusion in the published studies |
| Duration studied | Acute, single-session protocols |
| Evidence level | Limited Human Evidence |
| Last reviewed | 2026-09-26 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Intravenous bolus study of kisspeptin-112-121, i.e. kisspeptin-10 (Galbiati et al., 2025)Clinical trial · Human physiology study | Healthy adults (n=12, 50% female) | 0.24 nmol/kg bolus of kisspeptin-112-121 | Intravenous | Single bolus | Acute | Oxytocin response, by sex | Sex-dependent increases in oxytocin levels in response to intravenous kisspeptin in humans. Eur J Endocrinol. 2025. |
| NCT03771326 — insulin secretion in menClinical trial · Registered trial, completed, no results posted | Men (n=14) | Per trial protocol | Intravenous | — | — | Insulin secretion | NCT03771326 — KP-10 and Insulin Secretion in Men |
Preclinical and analog research
Not human dosing evidence. Listed for completeness and never extrapolated to a human dose.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| Intranasal study (Mills et al., 2025) — used kisspeptin-54, the 54-residue parent, not kisspeptin-10Clinical trial · Human physiology study of the parent peptide (analog evidence)Studied an analog, not Kisspeptin-10 itself | Healthy adults across several study groups | 12.8 nmol/kg | Intranasal | Single administration | Acute | Luteinising hormone response | Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine. 2025. |
| Bone metabolism study (Comninos et al., 2022) — used kisspeptin-54, the 54-residue parent, not kisspeptin-10Clinical trial · Human physiology study of the parent peptide (analog evidence)Studied an analog, not Kisspeptin-10 itself | Healthy men | 1 nmol/kg/h intravenous infusion for 90 minutes (kisspeptin-54) | Intravenous | — | — | Bone formation and resorption markers | Acute Effects of Kisspeptin Administration on Bone Metabolism in Healthy Men. J Clin Endocrinol Metab. 2022. |
Where sources disagree
- Published human dosing is weight-based and given intravenously or intranasally in a laboratory setting, in nanomoles per kilogram. Kisspeptin-10 is sold for subcutaneous self-injection with fixed protocols commonly quoted around 100 mcg; those figures are several orders of magnitude away from the studied doses once converted, and no published study used that route.
- Kisspeptin-10 is the 112-121 fragment of kisspeptin-54. Studies are indexed under kisspeptin, KP-10, kisspeptin-112-121 and metastin, and evidence for the 54-residue parent is not automatically evidence for the 10-residue fragment.
- All published human work is acute and mechanistic — single doses measuring a hormone response over hours. Nothing establishes a repeated-dosing regimen or its safety over time.